Cox A C
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City 73190.
Toxicon. 1993 Nov;31(11):1445-57. doi: 10.1016/0041-0101(93)90210-a.
Deinagkistrodon acutus venom contains a collection of anticoagulant proteins that has been reported to prevent prothrombinase assembly (Teng and Seegers, 1981, Thromb. Res. 23, 255). A partial sequence indicates that these proteins are related to the functionally equivalent protein in Trimeresurus flavoviridis (Atoda et al., 1991, J. Biochem. 106, 808). Inhibition of prothrombinase, the complex of Factors Xa and Va combined with phospholipids, is expressed in bovine, human, and rat plasmas as indicated by an assay dependent on only prothrombinase activity. The concentration dependence of inhibition of prothrombin conversion by different combinations of the components of bovine prothrombinase under the same conditions yielded estimates of apparent dissociation constants of 104 nM and 2 nM for complexes of the inhibitor with Factor Xa and with Factors Xa and Va, respectively. Because this inhibitor does not prevent Factor Xa alone from converting prothrombin, but blocks the other combinations, we conclude the inhibitor prevents the complex of Factors Xa and Va from binding to phospholipid surfaces and to prothrombin. The inhibitor also blocks the activation of Factor X by Factor VIIa and thromboplastin as well. However, the inhibitor has no effect on thrombin-induced clotting or fibrinolysis induced by either plasminogen activator or streptokinase. Therefore, this inhibitor has several properties required of an anticoagulant, therapeutic agent.
五步蛇毒含有一系列抗凝蛋白,据报道这些蛋白可阻止凝血酶原酶组装(Teng和Seegers,1981年,《血栓研究》23卷,255页)。部分序列表明这些蛋白与竹叶青蛇中功能等效的蛋白相关(Atoda等人,1991年,《生物化学杂志》106卷,808页)。凝血酶原酶是由Xa因子和Va因子与磷脂结合形成的复合物,在牛、人及大鼠血浆中,仅依赖凝血酶原酶活性的检测表明其受到抑制。在相同条件下,牛凝血酶原酶各组分不同组合对凝血酶原转化抑制的浓度依赖性,得出抑制剂与Xa因子以及与Xa因子和Va因子复合物的表观解离常数估计值分别为104 nM和2 nM。由于该抑制剂并不阻止Xa因子单独将凝血酶原转化,但能阻断其他组合,我们得出结论,该抑制剂可阻止Xa因子和Va因子复合物与磷脂表面及凝血酶原结合。该抑制剂还能阻断VIIa因子和组织凝血活酶对X因子的激活。然而,该抑制剂对凝血酶诱导的凝血或纤溶酶原激活剂或链激酶诱导的纤维蛋白溶解均无影响。因此,这种抑制剂具有抗凝治疗药物所需的多种特性。